Cyllene Therapeutics News and Activities

Acquisition, funding and merger involving Cyllene Therapeutics.

• The new name of EG 427 is Cyllene Therapeutics. (posted on July 9 2026).

View the org chart displaying its 7 main executives

Most searched biographies at Cyllene Therapeutics

• Philippe Chambon, Chief Executive Officer and Chairman of the Board
• Mikael Contrastin, Vice President, Strategy and Business Developme...
• Astrid Valles-Sanchez, Vice President, Translational Research

Create your alert
to follow the executive moves at Cyllene Therapeutics.

Cyllene Therapeutics has 2,424 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• The new name of EG 427 is Cyllene Therapeutics. (posted on July 9 2026).
• Opthea will change its company name to Ceryvyn Therapeutics on Jul 9, 2026. (posted on July 9 2026).
• Tissium has just announced a $60 Million fundraising (posted on July 8 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by Cyllene Therapeutics

Social media about Cyllene Therapeutics

• Cyllene Therapeutics on Wikipedia, Google News & Yahoo Finance
• Cyllene Therapeutics on LinkedIn, X (Twitter) & YouTube